3 citations
,
May 2018 in “Experimental Dermatology” In this study, the researchers reported that patient impacts and symptoms of hidradenitis suppurativa, as assessed by HSIA and HSSA measures, are associated with clinical characteristics such as the number of abscesses and inflammatory nodules.
41 citations
,
June 2018 in “Journal of The American Academy of Dermatology” This study examined the therapeutic response to folliculitis decalvans treatments among 60 patients and found that earlier disease onset was linked to more severe cases, while a combination of rifampicin, clindamycin, tetracyclines, and intralesional steroids was most effective in controlling symptoms.
November 2025 in “Acta Dermato Venereologica” In this study, researchers reported that while systemic antibiotics are often chosen first for treating severe folliculitis decalvans, they have a high discontinuation rate, suggesting an urgent need for more effective immunomodulatory treatments.
36 citations
,
December 2015 in “Drugs” This review summarizes various drug treatments for hidradenitis suppurativa, noting their effectiveness, side effects, and high recurrence rates, but reports no new clinical findings.
68 citations
,
February 2015 in “Journal of the European Academy of Dermatology and Venereology” This study found that severe folliculitis decalvans was associated with its onset before age 25 and the presence of pustules, while tetracyclines and clindamycin plus rifampicin were effective treatments.